Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins - Wikidata - awgldk - TriplyDB

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

http://www.wikidata.org/entity/Q34492140

about

Naturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.The DE and FG loops of the HPV major capsid protein contribute to the epitopes of vaccine-induced cross-neutralising antibodies.

P2860

Q35861286-33D85F2F-905F-4CD2-B0CE-2C4EC8AB986B Q37526148-6E686106-2EA2-4486-AEED-67F50D1BA4BD

P2860

Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

http://www.wikidata.org/entity/Q34492140

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@ast

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@en

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@nl

type

label

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@ast

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@en

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@nl

prefLabel

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@ast

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@en

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@nl

P1433

Q34492140-B4BB0E72-A5D3-438F-9DC8-75D0BB6DB91F

P1476

Q34492140-FF3201BF-F2B1-489E-832D-785A35ED89ED

P2093

Q34492140-16348797-22BD-4059-AE9E-F4C913137978

Q34492140-52C82591-C296-45C7-9F01-C2A9905EA888

Q34492140-72CA77D8-D764-4744-833B-7120D2FD79B5

Q34492140-7D2309F6-FFE4-4CF6-AFCA-0233B1A4E4E6

Q34492140-E1EDBF9A-1490-4E06-A24F-8451CED550DF

Q34492140-F57B4DF8-E729-4048-B185-46CB7A4DF0A1

Q34492140-F8020697-9939-4D4C-8A73-39D21001E5E5

P2860

Q34492140-0D77FE52-F087-47FE-A27F-5584B121151E

Q34492140-0D918809-EDB5-437F-AF56-74FA13A50BB3

Q34492140-0E192E30-DB66-44A1-8FF5-E4BC0774F47A

Q34492140-103F95C7-629F-4CFD-AB5B-204B0992F061

Q34492140-1086E57E-404D-4D37-A0BB-218CC6561E57

Q34492140-10F691F1-71F1-4D87-9D72-A4A1C0D3B65D

Q34492140-14BBB928-B012-4A36-BC87-5B6048414FFF

Q34492140-152762BC-FBDC-4820-B930-F65BD68729D5

Q34492140-20DBCE1C-6FBB-4CA0-9823-0D17EC0620B3

Q34492140-28C081E4-283C-4356-A12E-A858139BF59A

P304

Q34492140-4033D647-9E96-40D7-8279-FED1A951F535

P31

Q34492140-F989223F-351F-4EBF-857D-EBCADCFA9425

P356

Q34492140-6E85B679-1347-4359-A835-8698983A6560

P407

Q34492140-40315AB4-A2A5-4AD0-A791-1897FD678BFD

P433

Q34492140-C07ED1C9-6A77-4CF8-B52E-D89A1AB0C1E6

P478

Q34492140-97C1162A-76EC-4992-903C-3486588DC1EC

P50

Q34492140-CD79ED79-FA77-406B-8472-3CFEA3394CFE

P577

Q34492140-17CE3EF9-BBF0-4EB6-970C-40010AC2C561

P5875

Q34492140-3DCEE7B5-059B-4729-8528-2F822B076ED5

P698

Q34492140-E92B2056-149E-4BC7-9B9C-1EBD3432DD8C

P932

Q34492140-A45501C7-81D0-47CE-911F-DE885BA040C6

P356

J.VACCINE.2014.07.116

P1433

P1476

Pre-clinical immunogenicity of ...... alpha-9 major capsid proteins

@en

P2093

Anna Godi

http://www.w3.org/2001/XMLSchema#string

Dianna E Wilkinson

http://www.w3.org/2001/XMLSchema#string

Eve Draper

http://www.w3.org/2001/XMLSchema#string

Giada Mattiuzzo

http://www.w3.org/2001/XMLSchema#string

Mark Page

http://www.w3.org/2001/XMLSchema#string

Philip Minor

http://www.w3.org/2001/XMLSchema#string

Sara L Bissett

http://www.w3.org/2001/XMLSchema#string

P2860

MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0

Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16

Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal)

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers.

Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial.

Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

P304

6548-6555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2014.07.116

http://www.w3.org/2001/XMLSchema#string

P407

P433

48

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265473510

http://www.w3.org/2001/XMLSchema#string

P698

25203446

http://www.w3.org/2001/XMLSchema#string

P932

4228199

http://www.w3.org/2001/XMLSchema#string